Document is current

Article History

Received: 6 February 2024

Accepted: 23 July 2024

First Online: 19 August 2024

Declarations

:

: Informed consent was obtained from all patients at the time of enrollment. This study was conducted in accordance with the Declaration of Helsinki and followed generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practice (GPP) issued by the International Society for Pharmacoepidemiology (ISPE), Pharmaceutical Research and Manufacturers Association (PhRMA) guidelines, and local regulations/guidelines for PMS. This study was approved by the Ministry of Food and Drug Safety (MFDS) and a total of 22 institutional review boards (IRBs) prior to data collection. The full name of each IRB was as follows. Samsung Medical Center IRB. Chung-Ang University Hospital IRB. Severance Hospital IRB. Seoul National University Hospital IRB. The Catholic University of Korea, Seoul ST. Mary’s Hospital IRB. Gangnam Severance Hospital IRB. The Catholic University of Korea, Daejeon ST. Mary’s Hospital IRB. Korea University Ansan Hospital IRB. Yeungnam University Medical Center IRB. Pusan National University Hospital IRB. Seoul National University Bundang Hospital IRB. The Catholic University of Korea, ST. Vincent’s Hospital IRB. Kosin University Gospel Hospital IRB. Pusan National University Yangsan Hospital IRB. Hanyang University Guri Hospital IRB. Keimyung University Dongsan Medical Center IRB. The Catholic University of Korea, Bucheon ST.Mary’s Hospital IRB. Asan Medical Center IRB. Wonju Severance Christian Hospital IRB. CHA University Bundang Medical Center IRB. Soon Chun Hyang University Hospital Seoul IRB. Soon Chun Hyang University Hospital Cheonan IRB.

: Not applicable.

: The authors do not have an actual or potential conflict of interest and do not have any interest to declare regarding this work. Joo-young Jo and Juwon Woo are employed by Pfizer Pharmaceuticals Korea Ltd. All the other authors have no competing interest.

: Not applicable.